US-based private equity Warburg Pincus agreed to sell 2.775 million common shares in China Biologic Products Inc (CBPO), one of the top three producers of plasma products in China, in an underwritten public offering, according to the statement.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
